^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    EBC-129

    i
    Other names: EBC-129, EBC129, EBC 129
    Associations

    News

    Trials
    Company:
    A*Star, National Cancer Centre Singapore
    Drug class:
    Microtubule inhibitor, CEACAM5-targeted antibody-drug conjugate, CEACAM6-targeted antibody-drug conjugate
    Related drugs:
    Associations

    News

    Trials
    8ms
    EBC-129-01: A Study of EBC-129 in Advanced Solid Tumours (clinicaltrials.gov)
    P1, N=84, Recruiting, EDDC (Experimental Drug Development Centre), A*STAR Research Entities | Trial completion date: Jun 2026 --> Dec 2026 | Trial primary completion date: Jun 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • EBC-129
    2years
    A Study of EBC-129 in Advanced Solid Tumours (clinicaltrials.gov)
    P1, N=84, Recruiting, EDDC (Experimental Drug Development Centre), A*STAR Research Entities | Trial completion date: May 2025 --> Jun 2026 | Trial primary completion date: Apr 2025 --> Jun 2026
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • EBC-129
    over2years
    A Study of EBC-129 in Advanced Solid Tumours (clinicaltrials.gov)
    P1, N=84, Recruiting, EDDC (Experimental Drug Development Centre), A*STAR Research Entities | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • EBC-129